CN114432356A - A composition for treating cancer and its preparation method - Google Patents
A composition for treating cancer and its preparation method Download PDFInfo
- Publication number
- CN114432356A CN114432356A CN202210170805.5A CN202210170805A CN114432356A CN 114432356 A CN114432356 A CN 114432356A CN 202210170805 A CN202210170805 A CN 202210170805A CN 114432356 A CN114432356 A CN 114432356A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- extract
- preparation
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 55
- 201000011510 cancer Diseases 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 72
- 239000003814 drug Substances 0.000 claims abstract description 60
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 23
- 241000729173 Cirsium japonicum Species 0.000 claims abstract description 21
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 21
- 241001114960 Selaginella doederleinii Species 0.000 claims abstract description 21
- 235000006533 astragalus Nutrition 0.000 claims abstract description 20
- 241001061264 Astragalus Species 0.000 claims abstract description 18
- 210000004233 talus Anatomy 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 239000000284 extract Substances 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 238000002156 mixing Methods 0.000 claims description 32
- 239000000843 powder Substances 0.000 claims description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 238000002791 soaking Methods 0.000 claims description 19
- 241001646826 Isodon rubescens Species 0.000 claims description 15
- 238000000227 grinding Methods 0.000 claims description 13
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 241000691155 Pteris multifida Species 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 244000179560 Prunella vulgaris Species 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 235000008113 selfheal Nutrition 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 3
- 241000045403 Astragalus propinquus Species 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 31
- 230000035755 proliferation Effects 0.000 abstract description 18
- 230000002401 inhibitory effect Effects 0.000 abstract description 17
- 208000024891 symptom Diseases 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 10
- 230000036407 pain Effects 0.000 abstract description 10
- 230000008929 regeneration Effects 0.000 abstract description 7
- 238000011069 regeneration method Methods 0.000 abstract description 7
- 230000007812 deficiency Effects 0.000 abstract description 6
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 238000013508 migration Methods 0.000 abstract description 5
- 241000721047 Danaus plexippus Species 0.000 abstract description 4
- 230000000235 effect on cancer Effects 0.000 abstract description 4
- 230000009545 invasion Effects 0.000 abstract description 4
- 230000005012 migration Effects 0.000 abstract description 4
- 210000001732 sebaceous gland Anatomy 0.000 abstract description 4
- 208000006083 Hypokinesia Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 12
- 241000180649 Panax notoginseng Species 0.000 description 11
- 235000003143 Panax notoginseng Nutrition 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000009636 Huang Qi Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 206010042674 Swelling Diseases 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 240000003152 Rhus chinensis Species 0.000 description 6
- 235000014220 Rhus chinensis Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 229940107666 astragalus root Drugs 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 235000018553 tannin Nutrition 0.000 description 5
- 229920001864 tannin Polymers 0.000 description 5
- 239000001648 tannin Substances 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000915604 Scutellaria barbata Species 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000003640 drug residue Substances 0.000 description 4
- -1 flavonoid compounds Chemical class 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000003631 expected effect Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- DUXQKCCELUKXOE-UHFFFAOYSA-N Pectolinarigenin-Biosid Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C(OC)=C2OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(C)O2)O)O1 DUXQKCCELUKXOE-UHFFFAOYSA-N 0.000 description 1
- SEXCCMQJDXQBOE-UHFFFAOYSA-N Pectolinarin Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C(OC)=C2OC1C(O)C(O)C(OC2C(C(O)C(O)C(C)O2)O)C(CO)O1 SEXCCMQJDXQBOE-UHFFFAOYSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001206332 Rhus potaninii Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010049750 Tumour haemorrhage Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- GPQLHGCIAUEJQK-UHFFFAOYSA-N pectolinarigenin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(O)C=C2O1 GPQLHGCIAUEJQK-UHFFFAOYSA-N 0.000 description 1
- KYDJXCOQYUPOKW-UHFFFAOYSA-N pectolinarigenin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccc(C)cc3 KYDJXCOQYUPOKW-UHFFFAOYSA-N 0.000 description 1
- DUXQKCCELUKXOE-CBBZIXHGSA-N pectolinarin Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C(OC)=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 DUXQKCCELUKXOE-CBBZIXHGSA-N 0.000 description 1
- QCCDLTOVEPVEJK-UHFFFAOYSA-N phenylacetone Chemical class CC(=O)CC1=CC=CC=C1 QCCDLTOVEPVEJK-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
The invention provides a composition for treating cancer and a preparation method thereof, relating to the technical field of traditional Chinese medicines. The composition for treating cancer mainly comprises the following raw materials in parts by weight: 3-5 parts of gallnut, 6-8 parts of Japanese thistle herb, 8-10 parts of astragalus, 8-10 parts of pseudo-ginseng, 3-5 parts of selaginella doederleinii and 15-20 parts of toad skin. The Chinese forest frog skin is used as a monarch drug, white liquid secreted by sebaceous gland glands of the Chinese forest frog skin is used for inhibiting the proliferation and regeneration of tumor cells, and gallnut, Japanese thistle herb and selaginella doederleinii are used as ministers for inhibiting the proliferation of the tumor cells, inducing the apoptosis of the tumor cells and inhibiting the invasion and migration of the tumor cells; the astragalus and the pseudo-ginseng can relieve pain caused by cancer and improve symptoms of qi deficiency, hypodynamia and the like of a patient while inhibiting the proliferation of tumor cells. Therefore, the medicines of the composition can be used in a compatible way, and have a better treatment effect on cancers. The preparation method of the composition can prepare the composition at low temperature, and avoid the damage of the components of the composition.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and particularly relates to a composition for treating cancer and a preparation method thereof.
Background
Cancer is a general term for a large group of malignant tumors. Cancer is a disease caused by emotional factors or excessive fatigue, physical exhaustion and overstrain of cancer cells in human internal organs. When the emotion of a person is greatly reduced or the person is strongly stimulated, the life movement in the body is also affected by the emotion, and the life movement is changed from ordered movement to disordered movement. The cells which do disordered movement form a tumor at which part, and the tumor grows indefinitely and endlessly, so that the nutrient substances in the body of a patient are greatly consumed; the cancer cells release various toxins, so that a series of symptoms are produced by a human body; cancer cells can also be transferred to all parts of the body to grow and reproduce, resulting in emaciation, weakness, anemia, inappetence, fever, and serious organ function impairment. In contrast, benign tumor is easy to remove, generally does not transfer and relapse, has only extrusion and blocking effects on organs and tissues, but cancer (malignant tumor) can also destroy the structures and functions of tissues and organs, cause necrotizing hemorrhage and infection, and finally die due to organ function failure. By the time science has progressed at a rapid pace, we have reason to believe that cancer is not an incurable disease.
The conventional cancer treatment methods include: surgical, radiation and chemotherapy; the surgical treatment can only aim at the excision operation of the parts where the cancer cells are gathered, and is suitable for patients with limited cancer cell range, no distant metastasis and good physique; the radiotherapy is a treatment method which utilizes high-energy electromagnetic radiation to act on a living body to change the structure of a biological molecule so as to achieve the purpose of destroying cancer cells, but normal cells of a human body can be destroyed at the same time of destroying the cancer cells, so that the human body is greatly damaged; chemotherapy essentially destroys cancer cells by "combating them with poison", but like radiotherapy, they also destroy normal cells of the body and harm the health of the body.
Based on the above, the composition for treating the cancer, which has no side effect and is not easy to relapse, has great significance.
Disclosure of Invention
The invention aims to provide a composition for treating cancer, which can inhibit the proliferation and metastasis of tumor cells and has better treatment effect on the cancer.
Another object of the present invention is to provide a method for preparing a composition for treating cancer, which can be prepared under a low temperature condition, and prevent the components of the composition from being damaged.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
In one aspect, the invention provides a composition for treating cancer, which comprises the following raw materials in parts by weight: 3-5 parts of gallnut, 6-8 parts of Japanese thistle herb, 8-10 parts of astragalus, 8-10 parts of pseudo-ginseng, 3-5 parts of selaginella doederleinii and 15-20 parts of toad skin.
In another aspect, the present invention provides a method for preparing a composition for treating cancer, which mainly comprises the following steps:
pulverizing Galla chinensis, herba seu radix Cirsii Japonici, and herba Selaginellae Doederleinii, soaking in ethyl acetate-ethanol mixture for 16-30 h, and performing solid-liquid separation to obtain medicinal liquid I and medicinal residue I;
soaking Notoginseng radix and radix astragali in ethanol solution for 1-2 h, and refluxing to obtain second medicinal liquid; mixing the first liquid medicine and the second liquid medicine, and concentrating to prepare a first extract;
grinding the toad skin to obtain medicinal powder, mixing the medicinal powder with yellow wine, and preparing an extract II; and mixing the first extract and the second extract to obtain the composition.
The composition for treating cancer and the preparation method thereof provided by the embodiment of the invention have at least the following beneficial effects:
the invention provides a composition for treating cancer, which comprises the following raw materials in parts by weight: 3-5 parts of gallnut, 6-8 parts of Japanese thistle herb, 8-10 parts of astragalus, 8-10 parts of pseudo-ginseng, 3-5 parts of selaginella doederleinii and 15-20 parts of toad skin. In the composition, the toad skin is used as a monarch drug, white liquid secreted by sebaceous gland glands of the toad skin is used for inhibiting the proliferation and regeneration of tumor cells, and then gallnut, Japanese thistle herb and selaginella doederleinii are used as ministers for further inhibiting the proliferation of the tumor cells, inducing the apoptosis of the tumor cells and inhibiting the invasion and migration of the tumor cells; the astragalus and the pseudo-ginseng in the composition can relieve pain caused by cancer and improve symptoms of qi deficiency, hypodynamia and the like of patients while inhibiting the proliferation of tumor cells. Therefore, the medicines of the composition can be used in a compatible way, and have a better treatment effect on cancers.
In addition, the present invention provides a method for preparing a composition for treating cancer, which can prepare a composition at a low temperature without damaging the components of the composition.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that, in the present application, the embodiments and features of the embodiments may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
The invention provides a composition for treating cancer, which mainly comprises the following raw materials in parts by weight: 3-5 parts of gallnut, 6-8 parts of Japanese thistle herb, 8-10 parts of astragalus, 8-10 parts of pseudo-ginseng, 3-5 parts of selaginella doederleinii and 1-3 parts of toad skin. The effects of the raw materials are as follows:
gallnut: gallnut is insect gall on leaves of Rhus chinensis Mill, Rhus potaninii Maxim, Rhus chinensis Mill, Rhus chinensis Maxim, or Rhus chinensis punjabensis Stew.var.sinica (Diels) Rehd.et Wils., mainly formed by parasitizing the gall aphid Melaphosis chinensis (Bell) Baker. Galla chinensis is sour, astringent and cold in nature, enters lung, large intestine and kidney meridians, has the effects of astringing lung, lowering fire, astringing intestine, relieving diarrhea, arresting sweating, arresting bleeding, astringing dampness and healing sore, and is mainly used for treating symptoms such as lung deficiency chronic cough, lung heat phlegm cough, chronic diarrhea chronic dysentery, spontaneous perspiration and night sweat, diabetes, hemafecia and hemorrhoidal bleeding, traumatic hemorrhage, carbuncle swelling and sore toxin, and skin wet and rotten. Researches show that the tannin component of the gallnut can destroy the tannin of tumor cells, so that the anti-tumor effect is achieved. Specifically, the main active component of the gallnut tannin is 1,2,3,4, 6-five-O-galloyl-beta-D-glucose, which can induce tumor cell apoptosis, block cell cycle, inhibit tumor angiogenesis and inhibit tumor cell invasion and migration, so that the gallnut tannin is compatible with other medicines in the composition to achieve the expected anticancer effect.
Herba seu radix Cirsii Japonici: cirsium japonicum is the dry aerial part of Cirsium japonicum Fisch.ex DC, belonging to Compositae, has sweet and bitter taste, cool nature, and heart and liver meridian entered, has effects of cooling blood, stopping bleeding, removing blood stasis, and relieving swelling, and is mainly used for treating epistaxis, hematemesis, hematuria, hematochezia, metrorrhagia and metrostaxis. It is worth mentioning that pectolinarin and 5,7 dihydroxy-6, 4' -dimethoxy flavone in Cirsium japonicum have strong anti-tumor effect.
Astragalus root: astragalus root, radix astragali, sweet in taste and warm in nature, enters spleen and lung channels, has effects of invigorating qi, consolidating superficial resistance, expelling toxin, expelling pus, inducing diuresis and promoting granulation, and is mainly used for treating qi deficiency, debilitation, chronic diarrhea, rectocele, spontaneous perspiration, edema, uterine prolapse, chronic nephritis proteinuria, diabetes and unhealed sore. The astragalus polysaccharide in the astragalus has an obvious inhibition effect on the proliferation speed of tumor cells, and when the astragalus polysaccharide is used together with gallnut, Japanese thistle herb or root and Chinese forest frog skin, the astragalus polysaccharide can synergistically enhance the treatment effect of the composition on cancers to achieve the expected effect.
Pseudo-ginseng: notoginseng radix is sweet in taste, slightly bitter in flavor and warm in nature, has effects of removing blood stasis, stopping bleeding, promoting blood circulation and relieving pain, and is mainly used for treating hemorrhage, traumatic injury, swelling and pain due to blood stasis, etc. Notoginseng radix contains various physiologically active substances such as polysaccharide, alkynol, oligopeptide, flavone, amino acid, fatty acid, etc., and Ginseng radix alkynol and Ginseng radix epoxy alkynol separated from Notoginseng radix has obvious proliferation inhibiting effect on various tumor cells. Meanwhile, the extract of the pseudo-ginseng has better anticancer effect on gastric cancer, laryngeal cancer, human skin T cell lymphoma Hut-97 and the like. Therefore, the pseudo-ginseng can be used together with the medicines in the composition, and further achieves a better anticancer effect.
Herba selaginellae: the selaginella doederleinii is also called as herba doederleinii, herba saikoe, herba lepidii and herba chrysolopsis, is sweet in taste, bitter and astringent in taste and cool in nature, enters lung, stomach and liver meridians, has the effects of dispelling wind, clearing lung-heat, relieving cough, detoxifying, relieving pain, clearing swelling, resisting cancer, removing dampness and the like, and is mainly used for diseases such as exogenous cough, lung heat cough, sore throat, rheumatic arthralgia, muscle and bone fracture, carbuncle sore, damp-heat jaundice, chorioepithelioma, lung cancer, liver cancer, laryngopharynx cancer, digestive tract cancer and the like. The selaginella doederleinii hieron contains abundant flavonoid compounds, alkaloid compounds, lignanoid compounds, organic acid compounds, coumarin compounds, sterol compounds and phenylpropanone compounds, so that the compounds have an obvious inhibition effect on enzymes in the proliferation and differentiation processes of tumor cells, and have a good inhibition effect on the proliferation of the tumor cells, namely a good anti-tumor effect.
Toad skin: the toad skin is pungent in flavor and cool in nature, enters liver, spleen, liver and large intestine channels, and has the effects of detoxifying and resisting cancer, diminishing inflammation and relieving swelling and the like. The toad skin can inhibit the regeneration of tumor cells, thereby achieving the anti-tumor effect. Specifically, the white venom secreted by the oviductus ranae epithelial gland has a good regeneration effect on the proliferation and regeneration of tumor cells, so that the expected anticancer effect is achieved. In addition, the toad skin can also treat hepatitis and tracheitis.
In conclusion, in the composition, the toad skin is taken as a monarch drug, the white liquid secreted by the sebaceous gland of the toad skin is used for inhibiting the proliferation and regeneration of tumor cells, and then the gallnut, the circium japonicum and the selaginella doederleinii are taken as ministers for further inhibiting the proliferation of the tumor cells, inducing the apoptosis of the tumor cells and inhibiting the invasion and migration of the tumor cells; the astragalus and the pseudo-ginseng in the composition can relieve pain caused by cancer and improve symptoms of qi deficiency, hypodynamia and the like of patients while inhibiting the proliferation of tumor cells. Therefore, the medicines of the composition can be used in a compatible way, and have a better treatment effect on cancers.
In the invention, the composition also comprises the following raw materials in parts by weight: 1-2 parts of Chinese brake herb and 2-4 parts of rabdosia rubescens. The effects of the raw materials are as follows:
pteris multifida: the Pteris multifida (also known as JIJIJIAOCAO, JINGBAO, FENGWEIFENG and WUZHICAO) is light in taste, slightly bitter in taste, and cool in nature, has effects of clearing heat and promoting diuresis, removing toxic substance and stopping dysentery, and cooling blood and stopping bleeding, and is mainly used for treating dysentery, gastroenteritis, hepatitis, urinary system infection, common cold and fever, sore throat, leucorrhea, metrorrhagia, etc. The Chinese brake herb has the inhibition activity on tumor cells and also has better anti-inflammatory and bacteriostatic effects, such as staphylococcus aureus, bacillus subtilis, escherichia coli, penicillium, aspergillus niger and the like.
Rabdosia rubescens (Hemsl.) Hara: rabdosia rubescens (also called broken rice and rice), is bitter and sweet in taste, slightly cold in nature, enters lung, stomach and liver channels, has the effects of clearing heat and removing toxicity, promoting blood circulation and relieving pain and the like, and is mainly used for treating sore throat, abdominal mass, lump in the abdomen, snake and insect bite and other diseases. Rabdosia rubescens has anticancer effect and also has good anti-inflammatory effect.
In conclusion, when the composition contains the Chinese brake herb and the rabdosia rubescens, the anticancer effect can be further enhanced, and the anti-inflammatory and bacteriostatic effects of the composition can be improved.
In the invention, the composition also comprises 0.5 to 1 weight part of selfheal and 1 to 3 weight parts of sculellaria barbata. The selfheal is pungent, bitter and cold in taste, enters liver and gallbladder channels, has the effects of clearing heat and purging fire, improving eyesight, eliminating stagnation and reducing swelling and the like, and is mainly used for diseases such as conjunctival congestion, swelling and pain, headache, dizziness, eyeball nyctalgia and the like. The barbat skullcap is pungent in flavor and neutral in nature, has the effects of clearing heat and removing toxicity, promoting blood circulation to remove blood stasis, relieving swelling and pain and the like, and is mainly used for treating appendicitis, hepatitis, stomachache, early liver cancer, lung cancer, cervical cancer, mastitis and other diseases. The selfheal and the barbed skullcap herb have the effects of clearing away heat and toxic materials and improving the cancer symptoms of patients while having the anticancer effect.
In the invention, 0.5-1 part by weight of the serum can be added, which has the effects of cooling blood, stopping bleeding, clearing heat and detoxifying, can prevent the occurrence of tumor bleeding and the like, and has good treatment effect.
The invention also provides a preparation method of the composition for treating cancer, which mainly comprises the following steps:
pulverizing Galla chinensis, herba seu radix Cirsii Japonici, and herba Selaginellae Doederleinii, soaking in ethyl acetate-ethanol mixture for 16-30 h, and performing solid-liquid separation to obtain medicinal liquid I and medicinal residue I; soaking Notoginseng radix and radix astragali in ethanol solution for 1-2 h, and refluxing to obtain second medicinal liquid; mixing the first liquid medicine and the second liquid medicine, and concentrating to prepare a first extract; grinding the toad skin to obtain medicinal powder, and mixing the medicinal powder with yellow wine to obtain extract II; and mixing the first extract and the second extract to obtain the composition.
Specifically, nutgall, circium japonicum and selaginella doederleinii hieron are soaked in an ethyl acetate-ethanol mixed solution for 16h-30h, and filtered to obtain a first liquid medicine and a first residue medicine. At this time, the main component of tannin in gallnut can be fully dissolved into the ethanol solvent, the main component of Japanese thistle can be dissolved into the ethanol solvent, the effective component in selaginella doederleinii can be dissolved into the ethyl acetate solvent, the dissolution rate of the raw materials in the solvent is increased, and the action effect of the composition is improved.
In the application, the effective active ingredients in gallnut, Japanese thistle herb and selaginella doederleinii hieron are extracted by using an ethyl acetate-ethanol mixed solution as a solvent, wherein the volume ratio of ethyl acetate to ethanol (60 voL% -70 voL%) is 1 (3-4). Under the condition of the proportion, the proportion of the ethyl acetate to the ethanol is reasonable, so that the extraction efficiency of the effective components in the gallnut, the Japanese thistle herb and the selaginella doederleinii is higher.
In the application, in order to improve the dissolution of effective active ingredients in the medicine, the medicine can be extracted under negative pressure in the leaching process, and the negative pressure is-0.05 MPa to-0.03 MPa. Under the negative pressure condition, the effective active ingredients in the drug cells can be transferred from the cell wall to the solvent under the action of the negative pressure, and the dissolution efficiency is higher.
In the application, the separated first herb residue is ground into first medicinal powder, the first medicinal powder and the first medicinal liquid are mixed, and then the mixture is prepared into first extract. At the moment, the liquid medicine remained in the first decoction dregs can be mixed with the first decoction, so that the utilization rate of the liquid medicine is improved, and meanwhile, the solid components in the medicinal powder can be used as a filling agent, so that when the composition is prepared into tablets, pills and capsules, the addition amount of the filling agent can be reduced, the cost is reduced, and the cost performance of the composition is improved. When the content of the filler is small, the volume of the tablet/pill is small, and at the moment, the situation that a patient loses, falls and the like easily occurs when carrying the medicine, so that the convenience is not high. The above problem can be solved by mixing the first herb residue and the first herb liquid.
In the application, the material-liquid ratio of the first herb residue to the concentrated first herb liquid is 1 (0.3-0.6) g/L, so that the granular feel of the first extract is reduced, and the quality of the first extract is uniform.
In the application, pseudo-ginseng and astragalus are soaked in an ethanol solution for 1 to 2 hours, and then heated and refluxed at the temperature of 50 to 55 ℃ to prepare a second liquid medicine. At the moment, the effective components in the pseudo-ginseng and the astragalus can be extracted, and impurities can be removed through heating reflux, so that the medicine effect of the composition is better.
And then mixing the first liquid medicine and the second liquid medicine, and concentrating to obtain a first extract.
Then grinding the dried toad skin to prepare medicinal powder, so that the white liquid on the toad skin can be used as the medicinal powder to achieve the expected effect. In the application, in order to reduce the fishy smell of the toad skin, the medicinal powder is mixed with the yellow wine to prepare the second extract, so that the prepared composition is low in oral administration difficulty and better in drug effect.
In the application, the ratio of the medicinal powder to the yellow wine is 10 (1-1.5) g/L.
In the application, the first extract and the second extract are mixed to prepare the composition.
In order to further reduce the difficulty of taking the composition, the composition is mixed with a filler to prepare a capsule, and the mass ratio of the composition to the filler is 1 (0.3-0.8).
In the application, the phoenix-tail fern, the rabdosia rubescens, the selfheal and the sculellaria barbata are mixed with the pseudo-ginseng and the astragalus mongholicus, and are extracted by ethanol to prepare a second liquid medicine.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
The present example aims to provide a composition for treating cancer, which is prepared from the following raw materials:
4kg of gallnut, 7kg of Japanese thistle herb, 9kg of astragalus, 9kg of pseudo-ginseng, 4kg of selaginella doederleinii and 17kg of toad skin.
The preparation method of the composition comprises the following steps:
pulverizing Galla chinensis, herba seu radix Cirsii Japonici, and herba Selaginellae Doederleinii, soaking in ethyl acetate-ethanol (volume ratio of ethyl acetate to 65 voL% ethanol is 1:3.5) mixture, soaking under negative pressure of-0.04 MPa for 24 hr, and filtering to obtain first medicinal liquid and first medicinal residue; soaking Notoginseng radix and radix astragali in ethanol solution for 1.5h, and refluxing at 55 deg.C to obtain second medicinal liquid; mixing the first liquid medicine and the second liquid medicine, and concentrating to prepare a first extract; grinding the toad skin to obtain medicinal powder, mixing the medicinal powder with yellow wine, wherein the material-liquid ratio of the medicinal powder to the yellow wine is 10:1.2g/L, and preparing an extract II; and mixing the first extract and the second extract to obtain the composition.
Example 2
The present example aims to provide a composition for treating cancer, which is prepared from the following raw materials:
4kg of Chinese gall, 7kg of Japanese thistle herb, 9kg of astragalus root, 9kg of pseudo-ginseng, 4kg of selaginella doederleinii, 17kg of Chinese forest frog skin, 1.5kg of phoenix-tail fern and 2kg of rabdosia rubescens.
The preparation method of the composition comprises the following steps:
pulverizing Galla chinensis, herba seu radix Cirsii Japonici, and herba Selaginellae Doederleinii, soaking in ethyl acetate-ethanol (volume ratio of ethyl acetate to 65 voL% ethanol is 1:3.5) mixture, soaking under negative pressure of-0.04 MPa for 24 hr, and filtering to obtain first medicinal liquid and first medicinal residue; and then grinding the first medicine residue and mixing with the first medicine liquid, wherein the material-liquid ratio of the first medicine residue to the first medicine liquid is 1:0.4 g/L. Soaking Notoginseng radix, radix astragali, herba Pteridis Multifidae and Rabdosia Rubescens (Hemsl.) Hara in ethanol solution for 1.5h, and refluxing at 55 deg.C to obtain second medicinal liquid; mixing the first liquid medicine (containing the first drug residue) and the second liquid medicine, and concentrating to prepare a first extract; grinding the toad skin to prepare medicinal powder, and mixing the medicinal powder with yellow wine, wherein the material-liquid ratio of the medicinal powder to the yellow wine is 10:1.2g/L, so as to prepare an extract II; and mixing the first extract and the second extract to obtain the composition.
Example 3
The present example aims to provide a composition for treating cancer, which is prepared from the following raw materials:
4kg of gallnut, 7kg of Japanese thistle herb, 9kg of astragalus, 9kg of pseudo-ginseng, 4kg of selaginella doederleinii, 17kg of Chinese forest frog skin, 1.5kg of Chinese brake herb, 3kg of rabdosia rubescens, 0.8kg of selfheal and 2kg of barbed skullcap herb.
The preparation method of the composition comprises the following steps:
pulverizing Galla chinensis, herba seu radix Cirsii Japonici, and herba Selaginellae Doederleinii, soaking in ethyl acetate-ethanol (volume ratio of ethyl acetate to 65 voL% ethanol is 1:3.5) mixture, soaking under negative pressure of-0.04 MPa for 24 hr, and filtering to obtain first medicinal liquid and first medicinal residue; and then grinding the first medicine residue and mixing with the first medicine liquid, wherein the material-liquid ratio of the first medicine residue to the first medicine liquid is 1:0.4 g/L. Soaking Notoginseng radix, radix astragali, herba Pteridis Multifidae, Rabdosia Rubescens (Hemsl.) Hara, Prunellae Spica and herba Scutellariae Barbatae in ethanol solution for 1.5h, and refluxing at 55 deg.C to obtain second medicinal liquid; mixing the first liquid medicine (containing the first drug residue) and the second liquid medicine, and concentrating to prepare a first extract; grinding the toad skin to obtain medicinal powder, mixing the medicinal powder with yellow wine, wherein the material-liquid ratio of the medicinal powder to the yellow wine is 10:1.2g/L, and preparing an extract II; and mixing the first extract and the second extract to obtain the composition.
Example 4
The present example aims to provide a composition for treating cancer, which is prepared from the following raw materials:
gallnut 3kg, Japanese thistle herb 6kg, astragalus root 8kg, notoginseng 8kg, selaginella doederleinii 3kg, Chinese forest frog skin 15kg, Chinese brake herb 1kg, rabdosia rubescens 2kg, selfheal 0.5kg and barbed skullcap herb 1 kg.
The preparation method of the composition comprises the following steps:
pulverizing Galla chinensis, herba seu radix Cirsii Japonici, and herba Selaginellae Doederleinii, soaking in ethyl acetate-ethanol (volume ratio of ethyl acetate to 60 voL% ethanol is 1:3) mixture for 16h under negative pressure of-0.05 MPa, and filtering to obtain first medicinal liquid and first medicinal residue; and then grinding the first medicine residue and mixing with the first liquid medicine, wherein the material-liquid ratio of the first medicine residue to the first liquid medicine is 1:0.3 g/L. Soaking Notoginseng radix, radix astragali, herba Pteridis Multifidae, Rabdosia Rubescens (Hemsl.) Hara, Prunellae Spica and herba Scutellariae Barbatae in ethanol solution for 1h, and refluxing at 50 deg.C to obtain second medicinal liquid; mixing the first liquid medicine (containing the first drug residue) and the second liquid medicine, and concentrating to prepare a first extract; grinding the toad skin to obtain medicinal powder, mixing the medicinal powder with yellow wine, wherein the material-liquid ratio of the medicinal powder to the yellow wine is 10:1g/L, and preparing an extract II; and mixing the first extract and the second extract to obtain the composition.
Mixing the composition with filler at a mass ratio of 1:0.3, and making into capsule.
Example 5
The present example aims to provide a composition for treating cancer, which is prepared from the following raw materials:
5kg of gallnut, 8kg of Japanese thistle herb, 10kg of astragalus root, 10kg of pseudo-ginseng, 5kg of selaginella doederleinii, 20kg of Chinese forest frog skin, 2kg of Chinese brake herb, 4kg of rabdosia rubescens, 1kg of selfheal and 3kg of barbed skullcap herb.
The preparation method of the composition comprises the following steps:
pulverizing Galla chinensis, herba seu radix Cirsii Japonici, and herba Selaginellae Doederleinii, soaking in ethyl acetate-ethanol (volume ratio of ethyl acetate to 70 voL% ethanol is 1:4) mixture for 30h under negative pressure of-0.03 MPa, and filtering to obtain first medicinal liquid and first medicinal residue; and then grinding the first medicine residue and mixing with the first medicine liquid, wherein the material-liquid ratio of the first medicine residue to the first medicine liquid is 1:0.6 g/L. Soaking Notoginseng radix, radix astragali, herba Pteridis Multifidae, Rabdosia Rubescens (Hemsl.) Hara, Prunellae Spica and herba Scutellariae Barbatae in ethanol solution for 2 hr, and refluxing at 53 deg.C to obtain second medicinal liquid; mixing the first liquid medicine (containing the first drug residue) and the second liquid medicine, and concentrating to prepare a first extract; grinding the toad skin to obtain medicinal powder, mixing the medicinal powder with yellow wine, wherein the material-liquid ratio of the medicinal powder to the yellow wine is 10:1.5g/L, and preparing an extract II; and mixing the first extract and the second extract to obtain the composition.
Mixing the composition with filler at a mass ratio of 1:0.8, and making into capsule.
Examples of effects
The composition prepared in example 3 is taken orally as an oral product, and the taking method is as follows: the medicine should be stopped after 9 days, and administered 1 time per day.
The first patient, 42 years old, male, who lives in Guizhou, has severe colon cancer, has symptoms of diarrhea, hemafecia, limb weakness and abnormal defecation, and after taking the composition, the symptoms are improved and the condition is improved;
the second patient, 60 years old, female, who lives in Guizhou, has lung cancer, the tumor size is 4.2 cm, after taking the composition, the patient has no metastasis and enlargement of the tumor and has improved symptoms after two-month return visit survey;
patients three, 48 years old, female, who live in Guizhou, have rectal cancer, have the symptoms of bloody stool and constipation after the rectal digital examination, improve the symptoms after taking the composition, have better disease conditions, and have no metastasis and growth after examination.
In summary, the invention provides a composition for treating cancer, which comprises the following raw materials in parts by weight: 3-5 parts of gallnut, 6-8 parts of Japanese thistle herb, 8-10 parts of astragalus, 8-10 parts of pseudo-ginseng, 3-5 parts of selaginella doederleinii and 15-20 parts of toad skin. In the composition, the toad skin is used as a monarch drug, white liquid secreted by sebaceous gland glands of the toad skin is used for inhibiting the proliferation and regeneration of tumor cells, and then gallnut, Japanese thistle herb and selaginella doederleinii are used as ministers for further inhibiting the proliferation of the tumor cells, inducing the apoptosis of the tumor cells and inhibiting the invasion and migration of the tumor cells; the astragalus and the pseudo-ginseng in the composition can relieve pain caused by cancer and improve symptoms of qi deficiency, weakness and the like of patients while inhibiting the proliferation of tumor cells. Therefore, the medicines of the composition can be used in a compatible way, and have a better treatment effect on cancers.
In addition, the present invention provides a method for preparing a composition for treating cancer, which can prepare a composition at a low temperature without damaging the components of the composition.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (10)
1. The composition for treating cancer is characterized by comprising the following raw materials in parts by weight: 3-5 parts of gallnut, 6-8 parts of Japanese thistle herb, 8-10 parts of astragalus, 8-10 parts of pseudo-ginseng, 3-5 parts of selaginella doederleinii and 15-20 parts of toad skin.
2. The composition for treating cancer according to claim 1, further comprising the following raw materials in parts by weight: 1-2 parts of Chinese brake herb and 2-4 parts of rabdosia rubescens.
3. The composition for treating cancer according to claim 1 or 2, further comprising the following raw materials in parts by weight: 0.5-1 part of selfheal and 1-3 parts of sculellaria barbata.
4. A method of preparing a composition for treating cancer according to any one of claims 1 to 3, comprising the steps of:
pulverizing Galla chinensis, herba seu radix Cirsii Japonici, and herba Selaginellae Doederleinii, soaking in ethyl acetate-ethanol mixture for 16-30 h, and performing solid-liquid separation to obtain medicinal liquid I and medicinal residue I;
soaking the pseudo-ginseng and the astragalus mongholicus in an ethanol solution for 1-2 hours, and refluxing to prepare a second liquid medicine; mixing the first liquid medicine and the second liquid medicine, and concentrating to prepare a first extract;
grinding the toad skin to obtain medicinal powder, and mixing the medicinal powder with yellow wine to obtain a second extract; and mixing the first extract and the second extract to obtain the composition.
5. The method according to claim 4, wherein the extraction is performed under negative pressure in a range of-0.05 MPa to-0.03 MPa during the immersion in the ethyl acetate-ethanol mixture.
6. The preparation method of claim 5, wherein the volume ratio of ethyl acetate to 60 voL-70 voL% ethanol in the ethyl acetate-ethanol mixture is 1 (3-4).
7. The preparation method of claim 4, wherein the residue is ground and then mixed with the first liquid medicine, and then mixed with the second liquid medicine to prepare the first extract.
8. The preparation method of claim 7, wherein the ratio of the first herb residue to the first liquid medicine is 1 (0.3-0.6) g/L.
9. The preparation method of claim 4, wherein the material-liquid ratio of the medicinal powder to the yellow wine is 10 (1-1.5) g/L.
10. The preparation method according to claim 4, wherein the composition is mixed with a filler in a mass ratio of 1 (0.3-0.8) to prepare a capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210170805.5A CN114432356A (en) | 2022-02-23 | 2022-02-23 | A composition for treating cancer and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210170805.5A CN114432356A (en) | 2022-02-23 | 2022-02-23 | A composition for treating cancer and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114432356A true CN114432356A (en) | 2022-05-06 |
Family
ID=81373520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210170805.5A Pending CN114432356A (en) | 2022-02-23 | 2022-02-23 | A composition for treating cancer and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114432356A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103223004A (en) * | 2013-04-08 | 2013-07-31 | 张宗升 | Chinese medicinal composition |
-
2022
- 2022-02-23 CN CN202210170805.5A patent/CN114432356A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103223004A (en) * | 2013-04-08 | 2013-07-31 | 张宗升 | Chinese medicinal composition |
Non-Patent Citations (3)
| Title |
|---|
| 张振海等: "不同品种及产地蟾皮中抗肿瘤活性成分含量比较", 《中华中医药杂志》 * |
| 徐坤元等: "干蟾皮、硇砂、三七治疗胃癌经验――仝小林三味小方撷萃", 《吉林中医药》 * |
| 李轶群等: "华蟾素注射液治疗中晚期恶性肿瘤41例", 《浙江中医药大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520607A (en) | Traditional Chinese medicine preparation used for treating gastritis | |
| CN108324921B (en) | A pharmaceutical composition with cyst removing and gastric mucosa protecting effects, and its preparation method | |
| CN112691130B (en) | Application of herba Aristolochiae rotundus and its extract in preparing medicine for treating gastrointestinal diseases and its pharmaceutical formulation | |
| CN110193064A (en) | A kind of Chinese medicine fecula application and preparation method thereof for pain caused by cancer | |
| CN112791175A (en) | Chinese and western medicine composition for improving human body metabolism function and discharging metabolic waste and preparation method thereof | |
| CN103933405A (en) | Pharmaceutical composition for treating qi-blood deficiency burn, and preparation method thereof | |
| CN102940808A (en) | Prescription medicine for treating lung cancer and preparation method | |
| CN104997860A (en) | Traditional Chinese medicine preparation for treating duodenal ulcer and preparation method thereof | |
| CN101618201A (en) | Medicine for curing vulvar leukoplakia | |
| CN104069443A (en) | Traditional Chinese medicine for treating acute purulent osteomyelitis and preparation method of traditional Chinese medicine | |
| CN114432356A (en) | A composition for treating cancer and its preparation method | |
| CN103417911A (en) | Traditional Chinese medicine composition for supporting chemo-treatment | |
| CN102698185B (en) | Traditional Tibetan medicine for treating hyperlipidemia and preparation method thereof | |
| CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
| CN109771567A (en) | A kind of formula of Chinese herbal medicine supporting vital QI and dispersing blood stasis toxin expelling tumour | |
| CN107854685A (en) | A kind of Chinese medicine composition with antitumor action and its production and use | |
| CN108635560A (en) | A kind of Chinese medicine and preparation method thereof for treating lymthoma | |
| CN103127398B (en) | Chinese medicament for treating cancers and preparation method thereof | |
| CN114129692B (en) | Traditional Chinese medicine composition for treating furunculosis and preparation method and application thereof | |
| CN107569576B (en) | Traditional Chinese medicine liver-nourishing and protecting compound preparation as well as preparation method and application thereof | |
| CN104740403A (en) | Medicine for treating blood-insufficiency and yin-deficiency recurrent oral ulceration and preparation method thereof | |
| CN113599460A (en) | Ganoderma lucidum composition for assisting in inhibiting tumors and preparation method thereof | |
| CN115607646A (en) | Composition for treating recurrent oral ulcer and chronic pharyngolaryngitis and preparation method thereof | |
| CN115337368A (en) | Medicine for treating various anorectal diseases and preparation method thereof | |
| CN103550337B (en) | Traditional Chinese medicine composition for treating female irregular menstruation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220506 |
|
| RJ01 | Rejection of invention patent application after publication |